Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Clin Cancer Res. 2017 May 2;23(16):4780–4792. doi: 10.1158/1078-0432.CCR-16-2622

Figure 1. High MCL1/low NOXA co-expression is associated with poor outcome in breast cancer patients.

Figure 1

Kaplan-Meier survival curves for overall survival (OS) and distant metastasis-free survival (DMFS) of breast cancer patients from the IBC World Consortium dataset, correlated to NOXA and MCL1 tumor mRNA levels. The log-rank test was used to compare survival curves for high and low MCL1 (A, D), high and low NOXA (B, E), and high or low MCL1 in correlation with low or high NOXA (C, F). The initial numbers of patients at risk in each group are indicated in the key.